Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson’s Disease Models
10.4062/biomolther.2021.077
- Author:
Hyeon Joo HAM
1
;
In Jun YEO
;
Seong Hee JEON
;
Jun Hyung LIM
;
Sung Sik YOO
;
Dong Ju SON
;
Sung-Su JANG
;
Haksup LEE
;
Seung-Jin SHIN
;
Sang Bae HAN
;
Jae Suk YUN
;
Jin Tae HONG
Author Information
1. College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28644, Republic of Korea
- Publication Type:Original Article
- From:Biomolecules & Therapeutics
2022;30(1):90-97
- CountryRepublic of Korea
- Language:English
-
Abstract:
Recently, increasing evidence suggests that neuroinflammation may be a critical factor in the development of Parkinson’s disease (PD) in addition to the ratio of acetylcholine/dopamine because dopaminergic neurons are particularly vulnerable to inflammatory attack. In this study, we investigated whether botulinum neurotoxin A (BoNT-A) was effective for the treatment of PD through its anti-neuroinflammatory effects and the modulation of acetylcholine and dopamine release. We found that BoNT-A ameliorated MPTP and 6-OHDA-induced PD progression, reduced acetylcholine release, levels of IL-1β, IL-6 and TNF-α as well as GFAP expression, but enhanced dopamine release and tyrosine hydroxylase expression. These results indicated that BoNT-A had beneficial effects on MPTP or 6-OHDA-induced PD-like behavior impairments via its anti-neuroinflammation properties, recovering dopamine, and reducing acetylcholine release.
